Clinical Guest Contributors

  1. AI In Medical Devices: Meeting The Regulatory Challenge Around The World, Part 2 5/13/2025

    This article focuses on the common regulatory threads that connect different regions and the global standards and principles being developed to bring consistency, safety, and trust to AI innovation in medical devices.

  2. How Recursion Is Industrializing Clinical Trials With AI 5/12/2025

    Recursion SVP of Clinical Development and Data Science Sid Jain discusses the company's three-point "ClinTech" strategy, focusing on AI-assisted trial design, trial execution, and evidence generation.

  3. The Potential Impact Of U.S. Tariffs On The Biotech Sector: Manufacturing, Funding, And Clinical Trials 5/12/2025

    Syner-G Biopharma Group's Raymond Forslund, Ph.D., MBA explores how U.S. tariffs might affect biotech manufacturing, funding, and clinical research.

  4. When To Outsource — And How To Pick The Perfect Clinical Trial Partners 5/9/2025

    EMED Technologies Director of Clinical Affairs Alex Nikanorov shares the company’s approach to deciding which clinical research functions to outsource and finding vendor partners that align with the company’s goals.

  5. Listen Up, Pharma: C. diff Patient Advocate Shares Tips To Better Understand Patients 5/8/2025

    The Peggy Lillis Foundation CEO Christian John Lillis discusses his experience advocating for C. diff therapies, highlighting some successes as well as shortcomings in feeling heard.

  6. Caregiver Distress: The Hidden Burden Of Dementia With Lewy Bodies — And Why Measuring It Matters 5/7/2025

    Taking care of a loved one can be challenging. Cognition Therapeutic experts contend that caregivers’ distress levels must be evaluated to better understand the impact of dementia with Lewy bodies (DLB) on patients, families, and society.

  7. How Close Is The First FDA-Approved Full-Spectrum Botanical Drug For Autism? 5/6/2025

    AJNA BioSciences CEO Joel Stanley details his transition from helping to build one of the largest CBD companies to developing what he hopes will become an FDA-approved botanical drug to treat the symptoms of autism.

  8. EMA Issues Draft Reflection Paper On Accelerating Biosimilar Approval 5/5/2025

    In April, the European Medicines Agency issued a draft of a new guidance document titled Reflection paper on a tailored clinical approach in biosimilar development. The public consultation runs until Sept. 30, 2025.

  9. DEI Was Never the Problem, The Way Pharma Did It Was 5/5/2025

    Consultant Denise Bronner details pharma's strategic rollback of DEI initiatives, roles, and even departments and explains why well-meaning but misguided intentions enabled their demise.

  10. Understanding The Impact Of An RMP On Patient Risks Using Relational Risk Analysis 5/5/2025

    Using relational risk analysis, let's take a closer look at risk management plans for identifying and managing adverse reactions for administering a new therapy to a patient.